2013 Bendigo Women's International (2) – Singles

XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study

Retrieved on: 
Monday, December 19, 2022
Clinical, Autosome, Part, ADPKD, Pharmacokinetics, Therapy, Polycystic kidney disease, Kidney disease, Control, FDA, XRX, 2013 Bendigo Women's International (2) – Singles, Marketing, Regulation, Pharmaceutical industry, Chemistry, EU

CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the completion of dosing in the XRX-OXY-101 pharmacokinetics bridging study (the “Study”).

Key Points: 
  • CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the completion of dosing in the XRX-OXY-101 pharmacokinetics bridging study (the “Study”).
  • Previously topline results from Part 1 and 2 have been reported in the Company’s press releases of July 13 and August 22, 2022.
  • Plasma sample analysis and topline results from both part 3 and part 4 are expected within the next several weeks.
  • Consolidated topline results from each part are anticipated to be reported in January 2023.